Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo, Merck in Global ADC Deal Worth Up to US$22 Billion
US Merck has bagged the global development and commercialization rights to three of Daiichi Sankyo’s antibody drug conjugate (ADC) assets, agreeing to pay up to US$22 billion, amid growing competition in the race to go after the emerging modality. The…
To read the full story
Related Article
- Daiichi, Merck Expand ADC Deal into Harpoon’s T-Cell Engager
August 8, 2024
BUSINESS
- Novartis, JSH Begin Project to Address Regional Gaps in Hematology Care
April 14, 2026
- Nxera to Receive US$22.5 Million Milestone as Schizophrenia Drug Enters PII
April 14, 2026
- Itochu Unit to Import Sodium, Potassium Chloride from Germany
April 14, 2026
- JCR Launches PIII Dose Comparison Study of Growject in Japan
April 14, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…